Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Deloitte
Covington
Chinese Patent Office
Federal Trade Commission
Healthtrust
US Army
McKinsey

Generated: January 21, 2019

DrugPatentWatch Database Preview

Telbivudine - Generic Drug Details

« Back to Dashboard

What are the generic sources for telbivudine and what is the scope of telbivudine patent protection?

Telbivudine is the generic ingredient in one branded drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telbivudine has sixty patent family members in twenty-one countries.

There are two drug master file entries for telbivudine.

Summary for telbivudine
International Patents:60
US Patents:7
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 2
Bulk Api Vendors: 53
Clinical Trials: 77
Patent Applications: 1,692
Formulation / Manufacturing:see details
DailyMed Link:telbivudine at DailyMed
Synonyms for telbivudine
1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-((2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-(2-Deoxy-beta-D-ribofuranosyl)-5-methyluracil
1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione
1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
1-(2-deoxy-beta-L-ribofuranosyl)-5-methyluracil
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
2-Deoxy-L-thymidine
2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-
2'-Deoxy-L-thymidine
26879-47-0
2OC4HKD3SF
3424-98-4
5-Methyl-1-beta-L-ribofuranosyl-2,4 -pyrimidinedione
AB01274717_02
AB01274717-01
AB2000195
AC-5632
AC1L4LJI
AKOS025117349
AN-10762
API0025947
b-L-2'-deoxy-thymidine
BC257880
BDBM50088372
beta-L-2'-Deoxythymidine
beta-L-Thymidine
BRD-K15976406-001-01-7
CHEBI:63624
CHEMBL374731
CS-1934
CT-990
D06675
D0CL9S
DB01265
DTXSID30187813
Epavudine
GC4386
HY-B0017
I14-8810
IQFYYKKMVGJFEH-CSMHCCOUSA-N
KB-81600
L-Deoxythymidine
L-dT
L-Thymidine
LdT
LDT-600
LDT600
LLT
LS-186402
LS-187347
MFCD02683612
MolPort-006-167-757
NB 02B
NCGC00346560-01
NU000198
NU001074
NU001351
NU007768
NV 02B
NV-02B
s1651
SCHEMBL124279
Sebivo
Sebivo;Tyzeka
Telbivudin
Telbivudine (Sebivo, Tyzeka)
Telbivudine (USAN/INN)
Telbivudine [USAN:INN:BAN]
Telbivudine [USAN]
Telbivudine, >=98% (HPLC)
Telbivudine(Tyzeka, Sebivo)
Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-
Tyzake/Sebivo (TN)
Tyzeka
Tyzeka (TN)
Tyzeka, Sebivo, Telbivudine
UNII-2OC4HKD3SF
Z2574360267
ZB000493
ZINC2159

US Patents and Regulatory Information for telbivudine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis TYZEKA telbivudine SOLUTION;ORAL 022154-001 Apr 28, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for telbivudine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
07/027 Ireland ➤ Try a Free Trial PRODUCT NAME: TELBIVUDINE AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/07/388/001 20070424
7 Finland ➤ Try a Free Trial
2007 00038 Denmark ➤ Try a Free Trial PRODUCT NAME: TELBIVUDINE
39/2007 Austria ➤ Try a Free Trial PRODUCT NAME: TELBIVUDIN
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
McKinsey
Medtronic
US Department of Justice
Chubb
Moodys
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.